資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/34588
|
| 標題: | Regular use of aspirin is associated with a lower cardiovascular risk in prostate cancer patients receiving gonadotropin-releasing hormone therapy |
| 作者: | Chang, Wei-Ting
Hong, Chon-Seng
Hsieh, Kun-Lin
Chen, Yi-Chen
Ho, Chung-Han
Shih, Jhih-Yuan
Kan, Wei-Chih
Chen, Zhih-Cherng
Lin, You-Cheng |
| 貢獻者: | Chi Mei Hospital
Southern Taiwan University of Science & Technology
National Cheng Kung University
Chia Nan University of Pharmacy & Science
Chi Mei Hospital
National Cheng Kung University
Chi Mei Hospital
Chia Nan University of Pharmacy & Science
Chi Mei Hospital
Chung Hua University
Chi Mei Hospital |
| 關鍵字: | agonists
mortality
disease
men
testosterone
taiwan
impact |
| 日期: | 2022 |
| 上傳時間: | 2023-12-11 13:59:20 (UTC+8) |
| 出版者: | FRONTIERS MEDIA SA |
| 摘要: | Gonadotropin-releasing hormone (GnRH) therapy has been known to increase risks of major adverse cardiovascular and cerebrovascular events (MACCEs). Herein, we aim to estimate whether regular use of aspirin attenuates risks of MACCEs in prostate cancer patients receiving GnRHs. Using Taiwanese National Health Insurance Research Database (NHIRD), we identified 7719 patients diagnosed with prostate cancer who were either aspirin-naive, received irregular or regular aspirin from 2008 to 2015. Through a multivariable logistic regression model, we investigated the impact of aspirin on MACCEs. Compared with nonusers and irregular users, most patients receiving regular aspirin were older and had more comorbidities. The crude incidence of one-year MACCEs was lowest in aspirin nonusers but highest in irregular users of aspirin compared with regular users of aspirin (2.65% vs. 4.41% vs. 2.85%, p=0.0099). After adjusting for age, cancer stage and comorbidities, irregular aspirin users had a higher risk of one-year MACCEs (adjusted OR: 1.33; 95% CI: 0.93-1.90, p=0.1139) than aspirin nonusers, but conversely, there was a trend of reducing the risk of MACCEs among those who received regular aspirin (adjusted OR: 0.79; 95% CI: 0.44-1.42, p=0.4256). In the subgroup analysis, there were age- and cancer stage-independent higher risks of MACCEs in patients who took aspirin irregularly compared to those in patients who did not take aspirin. The risks were attenuated in patients receiving regular aspirin. Collectively, regular use of aspirin presented a trend of reducing risks of MACCEs in prostate cancer patients receiving GnRHs. However, irregular use of aspirin diminished the benefits. |
| 關聯: | FRONTIERS IN ONCOLOGY, v.12, n.CB2, pp.CC2, pp.-2874, |
| 顯示於類別: | [行政單位] 123
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| index.html | | 0Kb | HTML | 89 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
